American Composer Peter Lieberson Dies of Lymphoma

Famed American composer, Peter Lieberson, died on Saturday in Israel. Diagnosed with lymphoma shortly after the death of his wife Lorraine Hunt Lieberson in 2006, Peter sought medical attention for his condition for extended periods of time – all the while never allowing it to ruin his desire to partake in the activity he loved most and was best at: composing music.

Born in New York in 1946, Lieberson gained critical acclaim in 1983 with a piano concert written for Peter Serkin. Serkin, over the years, would become a focal point of the composer’s success – serving as both an inspiration and strong endorser of his music.

Lieberson’s latest acclaimed work came when he put together “Neruda Songs,” a cycle of particular songs created to love poems by Pablo Neruda. This effort, in turn, earned him the Grawemeyer Award in 2008.

Lieberson was the son of the former head of Columbia Records, Goddard Lieberson. His mother, Vera Zorina, was a ballet dancer and actress.

A New York Times article by Alan Kozinn profiled Lieberson and portrayed him in a very fond light:

"Mr. Lieberson's works meld most of those influences into a cohesive, energetic and intensely communicative style, with brainy, atonal surfaces that attest to his post-tonal pedigree and a current of lyricism and drama that gives this music its warmth and passion," Kozinn wrote.

Lieberson is survived by his wife, and three children from his first marriage.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap